A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)

Inclusion Criteria: * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Previously diagnosed with multiple myeloma * Relapsed or refractory multiple myeloma with disease progression following one to three prior treatment regimens * Measurable multiple myeloma disease Exclusion Criteria: * Grade ≥ 2 peripheral neuropathy * Use of corticosteroids within 21 days prior to Day 1 * Use of other anti-myeloma therapy within 21 days prior to Day 1 * Intolerance to bortezomib or compounds containing boron * Life expectancy of \< 12 weeks * Current, recent, or planned participation in an experimental drug study * Active malignancy other than multiple myeloma within 5 years before screening * Prior treatment with bevacizumab * Inadequately controlled hypertension * Prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF) * Decreased left ventricular function at study entry * History of myocardial infarction or unstable angina within 6 months prior to Day 1 * History of stroke or transient ischemic attack within 6 months prior to Day 1 * Significant vascular disease or recent peripheral arterial thrombosis within 6 months prior to Day 1 * Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, including placement of a vascular access device within 7 days prior to Day 1 * History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 * Serious, non-healing wound, active ulcer, or untreated bone fracture (for pathologic bone fractures consistent with multiple myeloma, patients may be eligible if no treatment is planned) * Albuminuria * Known hypersensitivity to any component of bevacizumab * Pregnancy (positive pregnancy test) or lactation